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Abstract
Antibiotic resistance threatens effective treatment of microbial infections globally. This situation has spurred the hunt for new anti-
microbial compounds in both academia and the pharmaceutical industry. Here, we report how the widely used antitumor drug
cisplatin may be repurposed as an effective antimicrobial against the nosocomial pathogen Pseudomonas aeruginosa. Cisplatin was
found to effectively kill strains of P. aeruginosa. In such experiments, transcriptomic profiling showed upregulation of the recA
gene, which is known to be important for DNA repair, implicating that cisplatin could interfere with DNA replication in P. aerugi-
nosa. Cisplatin treatment significantly repressed the type III secretion system (T3SS), which is important for the secretion of
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exotoxins. Furthermore, cisplatin was also demonstrated to eradicate in vitro biofilms and in vivo biofilms in a murine keratitis
model. This showed that cisplatin could be effectively used to eradicate biofilm infections which were otherwise difficult to be
treated by conventional antibiotics. Although cisplatin is highly toxic for humans upon systemic exposure, a low toxicity was
demonstrated with topical treatment. This indicated that higher-than-minimal inhibitory concentration (MIC) doses of cisplatin
could be topically applied to treat persistent and recalcitrant P. aeruginosa infections.
Introduction
Pseudomonas aeruginosa is a leading nosocomial pathogen
which causes, among others, corneal, chronic otitis media,
urinary tract (UTI) and respiratory tract infections [1]. P. aerug-
inosa is also the main cause of fatal infections in patients with
cystic fibrosis (CF) [2] and cancer patients [3,4]. The success of
P. aeruginosa as a leading pathogen is attributed to its ability to
form resilient biofilms, resist antimicrobials and secrete viru-
lence products.
Microbial cells resident in biofilms are encased by an extracel-
lular matrix, which protects them from antimicrobial treatment
and the host’s immune clearance [5]. Clinical P. aeruginosa
isolates are mostly multidrug-resistant (MDR) strains [6], with
robust ability to form biofilms [7]. P. aeruginosa also secretes
virulence factors targeting important components of the
immune system, such as the type III secretion systems (T3SS),
which was shown to be associated with poor clinic outcomes in
patients with lower respiratory infections [8] and ventilator-as-
sociated pneumonia [9]. Identifying antimicrobial compounds
which actively target bacteria in the biofilm mode including
virulence mechanisms that cripple immune defenses, may offer
novel antimicrobial therapies against a variety of otherwise
persistent P. aeruginosa infections.
Here, we screened our in-house collection of FDA-approved
drugs and found that cisplatin was the most potent among
several other Pt(II)-based compounds to kill P. aeruginosa. It
was previously reported that cisplatin had antimicrobial effects
on nosocomial pathogens, such as Escherichia coli, Klebsiella
pneumonia and Staphylococcus aureus [10] and persister cells
[11]. Transcriptomic analysis was employed to reveal the mo-
lecular mechanisms on how cisplatin inhibits the growth and
production of virulence factors of P. aeruginosa. We also ex-
amined the effects of cisplatin treatment on in vitro P. aerugi-
nosa biofilms and in a mouse model of corneal infection
(keratitis). We showed that cisplatin is more effective than the
clinically used antibiotic tobramycin in eradicating biofilms. Al-
though cisplatin is highly toxic for intravenous applications, we
showed that it has low toxicity when applied topically to
wounds, as 25 mM (0.75 mg mL−1) did not have adverse effect
on wound healing. This meant that higher doses (5–10 × MIC)
of cisplatin could be safely used for topical applications. Given
the low topical toxicity of cisplatin, it may be utilized as an
attractive therapeutic agent for prevention and treatment of
P. aeruginosa biofilm infections.
Materials and Methods
Bacterial strains and culture media
The bacterial strains used in this study are listed in Supporting
Information File 1, Table S3. Luria–Bertani (LB) medium was
used to maintain the bacterial strains. Growth assay and static
biofilm cultivation were carried out at 37 °C in ABTGC (ABT
minimal medium [12] supplemented with 0.4 g/L glucose and
0.4 g/L casamino acids). For marker selection in P. aeruginosa,
30 μg mL−1 gentamycin (Gm), 50 μg mL−1 tetracycline (Tc),
100 μg mL−1 streptomycin (Strep) or 200 μg mL−1 carbeni-
cillin (Cb) were used, as appropriate.
Platinum complexes and solution
preparation for MIC assay
Cisplatin, transplatin, cDPCP, oxaliplatin, K2PtCl4 and cis-
PtCl2(CH3CN)2 were purchased from Sigma-Aldrich were used
as received. Platinum complexes cis-PtCl2(Py)2 [13,14] and cis-
PtCl2(PPh3)2 [15] were prepared according to the reported pro-
cedure. For minimal inhibitory concentration (MIC) assays,
cisplatin, cDPCP, oxaliplatin, K2PtCl4 and cis-PtCl2(CH3CN)2
were dissolved in saline solution (0.85% w/v) at 2.5 mM con-
centration, while transplatin, cis-PtCl2(Py)2  and cis-
PtCl2(PPh3)2 were dissolved in DMF (v/v) at 2.5 mM concen-
tration.
Determination of minimal inhibitory
concentration (MIC)
The MIC assays were performed using a microtiter broth dilu-
tion method as previously described (≈1 × 105 cells) in the
NACLAR guidelines [16]. Overnight cultures of bacterial
strains were diluted in ABTGC medium. Cisplatin and other
Pt-containing compounds were diluted from a stock solution
with ABTGC medium at a concentration 10 times higher than
the required range. 10 μL of each diluted solution of Pt com-
pounds were added to each corresponding well of a 96-well
microtiter plate (polypropylene, Costar) and 90 μL of diluted
bacterial culture in ABTGC medium were added before serial
dilutions. The plate was incubated at 37 °C for 16–18 h. MIC
was taken as the lowest concentration where no visual growth
(based on OD600) of bacteria was detected. The experiments
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were performed in triplicate and representative results were
shown.
RNA preparation
Bacterial cells were collected using the method described previ-
ously [17] with some modifications. Generally, PAO1 cells
were cultivated either with (1.5 μM) or without cisplatin. The
cells were harvested at the early-stationary phase (after approxi-
mately 8 h cultivation). Total RNA was extracted with an
RNeasy Protect Bacteria Mini Kit with on-column DNase
digestion (Qiagen). A Turbo DNA-free vigorous protocol was
used for a second round of DNase treatment (Ambion). The
16S, 23S and 5S rRNA was removed using the Ribo-Zero Mag-
netic Kit (Bacteria) (Epicentre).
RNA sequencing and data analysis
Gene expression analysis was conducted via Illumina RNA
sequencing (RNA-Seq technology). RNA-Seq was conducted
for two biological replicates of each sample. The rRNA-
depleted RNA was fragmented to 150–200 bp fragments, then
first and second strand cDNA were synthesized with a cDNA-
synthesis kit (ThermoScientific), followed by end repair and
adapter ligation. After 12 cycles of PCR enrichment, the quality
of the libraries was assessed using the Bioanalyzer (Agilent
Technologies, USA). The libraries were sequenced using the
Illumina HiSeq 2500 platform with a paired-end protocol and
read lengths of 100 nt.
The sequencing data was analyzed as described previously [12].
Sequence reads were mapped onto PAO1 reference genome
using the CLC genomics Workbench 8.0 (CLC Bio-Qiagen,
Aarhus, Denmark). The differentially expressed genes were
identified by performing a negative binomial test using the
DESeq [18] package of R/Bioconductor [19], using the cut off
of fold-change larger than 2 and a BH (Benjamini-Hochberg)
adjusted P-value smaller than 0.05. The raw sequence reads
were normalized by size factors, then Log2(N + 1) transformed.
Hierarchical clustering analysis was performed using the trans-
formed reads, and a heat-map was drawn for the differentially
expressed genes between the cisplatin treated cells and control
cells, using the heatmap.2 [19] package of R. Function enrich-
ment analysis was conducted based on PseudoCAP Function
Class (http://www.pseudomonas.com), and a dot plots figure
was generated using the ggplot2 [20] package of R.
The RNA-Seq datasets are available at the NCBI Sequence
Read Archives: SRS1038085 and SRS1038089.
qRT-PCR analysis
Total RNA was extracted using RNeasy Mini Kit (Qiagen) with
on-column DNase digestion. The integrity, purity and concen-
tration of the RNA were determined by NanoDrop spectropho-
tometry and Agilent 2200 TapeStation system.
Quantitative reverse transcriptase PCR (qRT-PCR) was per-
formed using a two-step method. First-strand cDNA was syn-
thesized from total RNA using SuperScript III First-Strand Syn-
thesis SuperMix kit (Cat. No. 18080-400, Invitrogen). The
cDNA was used as a template for qRT-PCR with a SYBR
Select Master Mix kit (Cat. No. 4472953, Applied Biosystems
by Life Technologies) on an Applied Biosystems StepOnePlus
Real-Time PCR System with the specific primers (see Support-
ing Information File 1, Table S4). The three genes of GAPDH,
gyrB, rpoD were used as endogenous control. Melting curve
analyses were employed to verify the specific single-product
amplification.
P. aeruginosa killing assay
The OD600 of overnight cultures of PAO1, ΔrecA and ΔrecA
complementation strains were measured and adjusted to 0.3 in
ABTGC medium with 0, 3.125, 6.25 and 12.5 µM cisplatin, re-
spectively. The strains were incubated at 37 °C with shaking at
200 rpm for 4 h. The cultures were then harvested, serially
diluted and plated on LB agar plates for incubation at 37 °C
overnight. Colonies on the plate were enumerated and colony
forming units (CFU) mL−1 were tabulated as follows:
CFU mL−1 = average number of colonies X dilution factor X
volume used to spread on LB agar plate. Experiments were con-
ducted in triplicate, and the results are shown as the mean ± s.d.
P. aeruginosa biofilm killing assay by
cisplatin and tobramycin
Biofilms were grown in 24-well plates (Nunc, Denmark) at
37 °C, as previously described [21]. Biofilms were washed
3 times with 0.9% NaCl and treated with ABTGC medium with
0, 3.125, 6.25 and 12.5 μM cisplatin, respectively. For tobra-
mycin treatment, biofilms were treated with ABTGC medium
with 5.3, 10.6 and 21.2 μM tobramycin, respectively. The
treated biofilms were incubated at 37 °C for 4 h. The biofilms
were harvested by scraping with a cell scraper, homogenized in
1 mL 0.9% NaCl, serially diluted and plated on LB agar plates
for incubation at 37 °C overnight. Colonies on the plate were
counted and CFU mL−1 was tabulated. Experiments were con-
ducted in triplicate, and results are shown as the mean ± s.d.
RAW264.7 macrophage cytotoxicity assay
The murine macrophages (RAW264.7) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Life
Technologies), supplemented with 10% fetal bovine serum
(FBS) (Gibco), in 75 cm2 cell culture flasks at a density
of 1.0 × 106 cells mL−1 at 37 °C, 5% CO2 for 72 h. The
5.0 × 106 macrophages per well were seeded in 24-well plate
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(Nunc, Denmark) and grown at 37 °C, 5% CO2 overnight. As
previously described [12], macrophages were washed once with
PBS and treated with PAO1 in DMEM medium with 0, 3.125,
6.25 and 12.5 µM cisplatin at a multiplicity of infection of
100 bacteria cells: 1 macrophage. As control, the macrophages
were treated with the T3SS deficient ΔpscJ mutant in DMEM
medium. The co-culture was incubated at 37 °C, 5% CO2 for
2 h. The extracellular bacterial cells in DMEM were removed
and the infected macrophages were washed 3 times with PBS.
Fresh DMEM was added to the infected macrophages and a
further incubation of the macrophages at 37 °C, 5% CO2 for 4 h
was ensued. A solution containing 20 µM propidium iodide (PI)
was added to the macrophages to stain for dead macrophages
killed by PAO1 treated with cisplatin or ΔpscJ. Live and dead
macrophages were imaged by fluorescence microscopy (Zeiss,
Germany) at 200× and tabulated under % of dead macrophages.
Experiments were conducted in triplicate, and the results are
shown as the mean ± s.d.
Rabbit corneal wound healing model
New Zealand White Rabbits (n = 4, weighing 2 to 3 kg) pur-
chased from National University of Singapore, were used for
this study. All animal experiments were conducted in compli-
ance with the ARVO statement for the Use of Animals in
Ophthalmic and Vision Research, the guide for the Care and
Use of laboratory animals (National Research Council) and
under the supervision of Singhealth Experimental Medical
Centre (SEMC).
Four rabbits were randomly grouped into two groups of two
rabbits each, comprising of the PBS control treated group and
0.75 mg mL–1 cisplatin treated group. Intra peritoneal injection
of 1 mL of ketamine (100 mg mL−1) and 0.5 mL of xylazil
(20 mg mL–1) had been used to anesthetize the rabbits. Corneas
were then anesthetized by topical administration of xylocaine
1%. A corneal wound was made by using a 5 mm trephine and
mechanical removal of epithelial cells was carried out by sterile
mini blade (BD-Beaver) leaving the basal lamina intact [22,23].
All the groups were treated by topical administration of the
respective drug 3 times per day. Cornea wound was visualized
by the aid of cobalt-blue filter equipped slit lamp biomi-
croscopy (New-generation Zoom clinical Slit Lamp, NS-2D,
Righton), staining with Minims fluorescein sodium eye drops
(Bausch and Lomb, 2% w/v) which is used in ophthalmology
clinic for disclosure of wound on the ocular surface [24,25].
Residual wound area (pixel square) was measured during the
wound healing process by Image-J 1.44o version. Mann-
Whitney U Test was employed to determine if a difference in
re-epithelialization existed among the different groups by using
GraphPad Prism 6.02. A probability value of p ≤ 0.05 was
considered statistically significant.
Murine model for corneal infection
The corneas of the C57BL/6 mice were scratched with a
scraper to create wounds. 10 µL of PAO1 planktonic cells
(≈1 × 106 cells) were dripped onto each cornea and incubated
for 24 h on the mice to allow the biofilms to form on the
scratched corneas as previously described [26,27]. About 10 µL
of cisplatin (final concentration 25 µM) or 0.9% NaCl as
control were dripped onto the cornea 3 times per day at 4 h
interval on the second day. The mice were kept for 72 h and
then sacrificed.
The corneas were harvested, and the biofilm was disrupted from
the corneas by crushing with mortar and pestle, followed by
vortexing with glass beads for 15 min. The homogenized
biofilm cells were serially diluted, plated on LB agar plates and
incubated at 37 °C overnight. The number of colonies was
counted, and CFU ml−1 was tabulated. Experiments were per-
formed in triplicate, and the results are shown as the mean ± s.d.
Results and Discussion
Cisplatin inhibits P. aeruginosa planktonic
growth
During our screening of in-house collection of FDA-approved
drugs against P. aeruginosa growth, we identified that cisplatin
had a minimal inhibitory concentration (MIC) of 6.25 μM
against the P. aeruginosa PAO1 lab strain (Figure 1). We
further tested the growth inhibitory effect of cisplatin against
another P. aeruginosa lab strain PA14 and a P. aeruginosa
mucoid multiple-drug resistant (MDR) CF clinical isolate
57388A and found that cisplatin had equivalent MIC at
6.25 μM against these two strains (Supporting Information
File 1, Table S3). We next evaluated several other Pt(II)-based
compounds for their growth inhibitory effects on P. aeruginosa,
but these tested compounds had higher MIC against P. aerugi-
nosa as compared to cisplatin (Figure 1).
Mode of action
The growth inhibitory effects of cisplatin on both eukaryotic
cells and microbial cells are attributed to the interactions of
Pt(II) in cisplatin with DNA [28-30]. To reveal the growth
arresting mechanisms and overall impact of cisplatin on the
physiology of P. aeruginosa, we performed an RNA-
sequencing (RNA-seq) based transcriptomic analysis on
P. aeruginosa PAO1 after cultivation in sub-lethal concentra-
tion (1.5 µM) of cisplatin for 8 hours and compared the tran-
scriptome with control transcriptomes of bacteria present in
cisplatin-free medium. Using a negative binomial test with a
BH adjusted P-value cut-off of 0.05 and a fold-change cut-off
of 2, we found that sub-MIC cisplatin treatment induced the
expression of 315 genes (Supporting Information File 1,
Table S1) while repressed the expression of 72 genes (Support-
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Figure 1: Structures and MICs of Pt-based compounds against P. aeruginosa PAO1.
ing Information File 1, Table S2) in P. aeruginosa. The heat-
map and function enrichment of the genes that were differently
expressed between cisplatin-treated and control P. aeruginosa
samples were illustrated in Figure 2 and Figure 3, respectively.
The cisplatin treatment triggered the expression of a large frac-
tion of the LexA-controlled SOS regulon [31], including genes
involved in DNA replication, recombination, modification and
repair (dnaE2, imuB, imuA, dinG, recA, recN, recX) and genes
involved in pyocin synthesis (PA0614-PA0648), whose expres-
sion were previously reported to be induced by ciprofloxacin
[31] and hydrogen peroxide treatments [32]. In addition,
cisplatin treatment induced the expression of a series of genes
involved in energy metabolism, which corroborated with
previous proteomics work showing that cisplatin could
interfere with stress response and energy metabolism in E. coli
[33].
To further validate the impact of cisplatin on DNA replication,
we compared the cisplatin sensitivity of the P. aeruginosa wild-
type PAO1 strain and its DNA recombination-deficient recA
mutant and found that the rec recombination pathway was
essential for the cisplatin resistance in P. aeruginosa (Figure 4).
Together with the transcriptome profiling, this result confirmed
that cisplatin was able to interact with the P. aeruginosa DNA,
resulting in up-regulation of stress response genes. This mecha-
nism was also similar to the mechanism of action by another
DNA crosslinker, mitomycin C which kills bacterial persister
cells [34].
Anti-T3SS effect of cisplatin
Our transcriptomic analysis also revealed the expression of a
large number of the secretion related genes, including those of
the type III secretion system (T3SS), which were downregu-
lated in PAO1 by cisplatin exposure (Table S2), which was sim-
ilar to that by ciprofloxacin exposure [31]. Our qRT-PCR analy-
sis confirmed that the expression of two selected T3SS genes,
exoS and pscG, were downregulated by cisplatin treatment com-
pared to control (Figure 5a). The downregulation of T3SS by
the LexA-controlled SOS response [35] could be attributed to
the induced expression of ptrB, a repressor of T3SS by cisplatin
treatment (Supporting Information File 1, Table S3).
The T3SS is one of the major virulence mechanisms employed
by P. aeruginosa and other microbial pathogens to impair the
host immune systems during infection [36,37]. T3SS activity of
P. aeruginosa was correlated with acute cytotoxicity to host
epithelial cells and immune cells such as macrophages and
neutrophils [38]. As we demonstrated that cisplatin treatment
was able to reduce the T3SS of P. aeruginosa, we further tested
the ability of cisplatin in attenuating the acute cytotoxicity of
P. aeruginosa to macrophages. Cisplatin treatment of P. aerugi-
nosa in the P. aeruginosa-macrophage co-cultures caused sig-
nificant less death of the mouse macrophages compared to
control samples (Figure 5b), suggesting the effectiveness of
cisplatin against P. aeruginosa infection.
Antibiofilm effect of cisplatin
P. aeruginosa is notorious for its biofilm formation capacity,
which might lead to persistent or recalcitrant infections. SOS
response and DNA recombination are required for development
of P. aeruginosa biofilm resistance [39-41]. Given cisplatin
treatment was able to interfere with DNA repair, we hypothe-
sized that cisplatin treatment could eradicate P. aeruginosa
biofilm cells. We compared the biofilm killing effects of
cisplatin and tobramycin at various concentrations. The MIC of
cisplatin and tobramycin against planktonic P. aeruginosa cells
were 6.25 µM and 2.65 µM, respectively. However, tobra-
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Figure 2: Transcriptomic analysis of control and cisplatin-treated PAO1 cultures. Heatmap comparing the transcriptomes of control and cisplatin-
treated PAO1 cultures.
mycin could not kill the biofilm cells at 2 × MIC due to its limi-
tation in biofilm penetration [42], while cisplatin was able to
kill substantial amount of biofilm cells with nearly 100 times
reduction of P. aeruginosa biofilm cells (Figure 6). This result
suggested that cisplatin might penetrate the biofilms better than
the otherwise eDNA trapped tobramycin to kill the P. aerugi-
nosa cells [42]. The 4 × MIC and 8 × MIC of tobramycin treat-
ment showed dose-dependent increase of biofilm killing
capacity (Figure 6). Interestingly, cisplatin had combinatory
effects with tobramycin in killing the PAO1 biofilms, as combi-
natorial treatment of 2 × MIC of cisplatin with 4 × MIC or
8 × MIC tobramycin killed the biofilm cells at a higher rate
compared to the mono-compound treatment (Figure 6). These
results suggest that combination of cisplatin and other conven-
tional antimicrobials could be a useful strategy for eradicating
persistent biofilm-associated infections.
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Figure 3: Function enrichment of differentially expressed genes from the transcriptomic analysis. A dot-lot figure was generated using ggplot2 the
package of R. Red circle highlights the genes involved in DNA replication and repair; blue circle highlights the genes involved in pyocin synthesis;
green circle highlights the genes involved in protein secretion (T3SS).
Cisplatin treatment attenuates P. aeruginosa
infection
As cisplatin could reduce the synthesis of T3SS-mediated viru-
lent products and kill biofilms of P. aeruginosa, we further
tested if cisplatin treatment was able to eradicate in vivo
P. aeruginosa infections using a mouse model of keratitis,
where P. aeruginosa cells have biofilm-like morphology
[26,27] and employ type III secretion during infections [43].
We firstly confirmed that cisplatin was not toxic and did not
interfere with wound healing, with no observable inflammation
or adverse effects, when applied topically on scratched corneas
with no bacterial infection (Supporting Information File 1,
Figure S1). We then allowed P. aeruginosa PAO1 to colonize
and establish infection in the scratched corneas of mice for 24 h.
10 µL of 1 × MIC (6.25 µM) of cisplatin and control 0.9%
NaCl were dripped at the site of P. aeruginosa infection 3 times
(4 hour interval) on the second day. The mice were sacrificed
on the third day and their corneas were harvested for CFU
count. Cisplatin showed efficient killing capacity on P. aerugi-
nosa cells from infected mouse corneas and there was a signifi-
cant reduction in the bacterial loads from the cisplatin treated
corneas as compared to the control corneas (Figure 7).
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Figure 4: Cisplatin fast-kill assay against the P. aeruginosa PAO1, ΔrecA mutant and the ΔrecACOM strain. P. aeruginosa strains were treated by
ABTGC medium with varies concentrations of cisplatin for 4 h. CFUs were determined for cisplatin-treated P. aeruginosa cultures. Means and s.d.
from triplicate experiments are shown.
Figure 5: Cisplatin treatment represses T3SS associated virulence. (A) Cisplatin treatment downregulated the expression of T3SS gene revealed by
qRT-PCR analysis. Means and s.d. from triplicate experiments are shown. Student’s t-test was performed for testing differences between groups.
*P ≤ 0.05. (B) Cisplatin treatment reduced cytotoxicity of P. aeruginosa PAO1 against mouse macrophage cells. Means and s.d. from triplicate experi-
ments are shown. Student’s t-test was performed for testing differences between groups. *P ≤ 0.05.
Conclusion
Here, we have demonstrated how cisplatin displays antiviru-
lence and antibiofilm effects against the opportunistic pathogen
P. aeruginosa. Since biofilms are notoriously difficult to be
cleared by conventional antibiotics, cisplatin possesses the addi-
tional advantage of killing biofilms. This makes cisplatin a
more attractive antimicrobial for treating biofilm infections clin-
ically. Even though cisplatin is known for its toxic side effects
on cancer patients when administered intravenously, we showed
indications that cisplatin could be applied topically to infection
sites with low toxicity and minimal negative impact on
wound repair. Transcriptomic analysis revealed that the
working mechanism of cisplatin towards P. aeruginosa is rather
unique and distinct from other conventional antibiotics, which
may offer alternative therapeutic approaches towards persistent
infections.
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Figure 6: P. aeruginosa biofilm killing assay by cisplatin, tobramycin and their combinations. P. aeruginosa biofilms were treated by ABTGC medium
with varies concentrations of cisplatin and or tobramycin for 4 h. CFUs were determined for cisplatin and or tobramycin-treated P. aeruginosa biofilms.
Means and s.d. from triplicate experiments are shown. Student’s t-test was performed for testing differences between groups. *P ≤ 0.05.
Figure 7: Cisplatin treatment attenuates P. aeruginosa infections.
CFU mL−1 of PAO1 obtained from corneas with and without cisplatin
treatment. Dotted horizontal lines represent limit of detection. The
mean and s.d. from six experiments were shown for in vivo biofilms.
Student’s t-test was performed for testing differences between groups.
*P < 0.01.
In recent years, metal-containing compounds have been identi-
fied as antimicrobial agents. Gallium was shown to disrupt the
iron metabolism of P. aeruginosa and efficiently kill estab-
lished biofilm [44]. In addition, the gold-containing drug, aura-
nofin, was found to be a broad-spectrum bactericidal com-
pound, that targets the thiol-redox homeostasis of a range of
Gram-positive bacteria [45]. Further studies will be carried out
to better understand the resistance mechanism and structural
requirements of the Pt-based compounds as an alternative to the
conventional antibiotics. Such compounds could also be used
synergistically with specific enzymes that degrade the biofilm
matrix [46] or biofilm-dispersal agents to boost the eradication
of biofilms, to provide better treatment options for chronic and
persistent infections.
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